Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.

Antoni Ribas(University of California, Los Angeles), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Jacob Schachter, Omid Hamid(Cedars-Sinai Medical Center), Wilson H. Miller(Jewish General Hospital), Razi Ghori(Merck & Co., Inc., Rahway, NJ, USA (United States)), Donald P. Lawrence(Massachusetts General Hospital), Inge Marie Svane(Copenhagen University Hospital), Rosalie Stephens(Auckland City Hospital), Henrik Schmidt(University of Southern Denmark), Georgina V. Long(The University of Sydney), Paola Queirolo, Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Victoria Atkinson(The University of Queensland), Matteo S. Carlino(The University of Sydney), Rohini Singh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Anna Maria Di Giacomo(University of Siena), Pier Francesco Ferrucci(MultiMedica)

Journal of Clinical Oncology

June 1, 2022

Cited by 8

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.9k

|New England Journal of Medicine|2014|5.3k

|Journal of Clinical Investigation|2017|3.9k

Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i><sup>V600E/K</sup>-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.